This site may receive compensation from the provider linked above. Full disclosure.
Weight loss and GLP-1 providers currently serving Medina County, Ohio — sourced from Google Business listings.
Weight loss service
2425 Medina Rd Suite 101, Medina, OH 44256
Weight loss service
15076 Pearl Rd, Strongsville, OH 44136
Medical clinic
Medina, OH
Business listings sourced from Google Maps. Information may not be current.
GLP-1 telehealth services are available to residents of all communities in Medina County, Ohio. Select your city for local information.
Medina County is a county in Ohio with a population of approximately 179,746 residents. Our telehealth platform connects patients across all communities in Medina County with board-certified physicians who can prescribe FDA-approved GLP-1 medications online. Ohio's mix of major metros (Columbus, Cleveland, Cincinnati) and extensive rural Appalachian southeast creates one of the most complex healthcare access landscapes in the Midwest. Ohio has been particularly hard-hit by metabolic disease in post-industrial communities.
GLP-1 receptor agonists — including semaglutide (Ozempic®, Wegovy®) and tirzepatide (Mounjaro®, Zepbound®) — are clinically proven weight loss medications. Ohio's adult obesity rate of 35.3% affects over 3.3 million residents. Franklin County (Columbus) is the most populous county and has seen obesity rates climb sharply. Southeast Ohio's Appalachian counties report obesity rates above 42%. Patients in Medina County can now access these treatments through a simple online consultation, without the need to travel to an in-person clinic.
Access Ozempic, Wegovy, Mounjaro, and Zepbound — all FDA-approved GLP-1 medications proven to support significant weight loss in clinical trials.
All prescribing physicians in our network hold active Ohio medical licenses. Consultations comply with Ohio telehealth law (Ohio Revised Code § 4731.296).
Our simple 3-step process makes getting a GLP-1 prescription easy for Medina County residents.
GLP-1 telehealth services are available across all Ohio counties. Browse neighboring counties below.
Explore GLP-1 telehealth availability across Ohio's major cities.
Yes. Ohio law permits telehealth prescriptions for GLP-1 medications after a proper clinical evaluation under Ohio Revised Code § 4731.296. Our network of Ohio-licensed physicians can complete your consultation online and send a prescription to your preferred pharmacy in Medina County or arrange home delivery.
Patients in Medina County can be prescribed semaglutide (Ozempic®, Wegovy®), tirzepatide (Mounjaro®, Zepbound®), and liraglutide (Saxenda®) — all FDA-approved GLP-1 receptor agonists indicated for weight management. Your physician will recommend the most appropriate option based on your health profile.
Consultation fees vary by provider, typically ranging from $0 to $199 for the initial visit. Medication costs depend on insurance coverage, manufacturer savings programs, and pharmacy choice. Many patients in Ohio qualify for significant savings through patient assistance programs.
After completing your online health assessment, most patients in Medina County receive a physician response within 24–48 hours. If approved, your prescription can be sent to a pharmacy near you in Medina County or shipped directly to your home within 2–5 business days.
Medina County has several local weight loss clinics and medical practices that may offer GLP-1 treatments in person. However, our telehealth service provides the same quality of care from the convenience of your home, with licensed Ohio physicians available to patients throughout Medina County.
Connect with experienced, US-licensed physicians specializing in metabolic health and GLP-1 therapy. All providers are board-certified and committed to evidence-based care.
Medically reviewed by
Dr. Sarah Mitchell, MD, ABOM
Board-Certified in Obesity Medicine • Last reviewed: June 5, 2026
Black Box Warning: In rodent studies, semaglutide and tirzepatide caused thyroid C-cell tumors. It is unknown whether GLP-1 receptor agonists cause thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans. These medications are contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Common side effects may include nausea, vomiting, diarrhea, constipation, abdominal pain, headache, and injection site reactions. These typically diminish as dosage is gradually escalated.
Serious side effects may include pancreatitis, gallbladder problems, kidney injury, hypoglycemia (with insulin), and allergic reactions. Consult your healthcare provider immediately if you experience severe symptoms.
Contraindications: History of medullary thyroid carcinoma, MEN 2, pancreatitis, pregnancy or breastfeeding, severe gastrointestinal disease. This is not a complete list — always discuss your full medical history with your physician.
Clinical References:
